09:24 AM EST, 11/04/2025 (MT Newswires) -- Metsera ( MTSR ) said Tuesday it has received an amended acquisition proposal from Novo Nordisk ( NVO ) that its board determined constitutes a "Superior Company Proposal" as defined under its existing merger agreement with Pfizer ( PFE ) .

The revised proposal values Metsera ( MTSR ) at up to roughly $10.0 billion, or up to $86.20 per share, representing an approximate 159% premium to Metsera's ( MTSR ) closing price as of Sept. 19, the last trading day before the Pfizer ( PFE ) deal was announced, the company said.

Pfizer ( PFE ) did not immediately reply to a request for comment.

MTSR shares were up past 1% premarket Tuesday.